مقالات پذیرفته شده در هفتمین کنگره بین المللی زیست پزشکی
Treatment of Acute Myeloid Leukemia in Children by CAR-T Cell Therapy: A Promising Approach
Treatment of Acute Myeloid Leukemia in Children by CAR-T Cell Therapy: A Promising Approach
Zahra Fathi,1Ehsan Rezaie,2,*
1. 1 Biotechnology, Department of Biology, Faculty of Basic Science, University of Ale Taha, Tehran, Iran 2. 2 Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran 1435916471, Iran
Introduction: Title: Treatment of Acute Myeloid Leukemia in Children by CAR-T Cell Therapy: A Promising Approach
Zahra Fathi , Ehsan Rezaei *
1 Biotechnology, Department of Biology, Faculty of Basic Science, University of Ale Taha, Tehran, Iran
2 Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran 1435916471, Iran
Abstract: Acute Myeloid Leukemia (AML) is a complex hematological malignancy primarily affecting children. The current standard of care for AML includes chemotherapy, stem cell transplantation, and targeted therapy. However, the clinical outcomes often remain suboptimal, highlighting the urgent need for novel therapeutic approaches. Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative treatment modality in various malignancies. The success of CAR-T therapy in pediatric leukemia, particularly in B-cell precursor Acute Lymphoblastic Leukemia (ALL), has encouraged exploration of its potential in AML. This article aims to review the current state-of-the-art clinical research and advancements in utilizing CAR-T cell therapy for treating pediatric AML. By targeting specific cell surface antigens expressed on leukemic blasts, CAR-T cells harness the immune system to recognize and eliminate cancer cells. High response rates, sustained remissions, and improved overall survival rates have been observed in preclinical and early-phase clinical trials utilizing CAR-T cell therapy in pediatric AML patients. However, several challenges, including antigen selection, antigen escape, cytokine release syndrome, and neurotoxicity, must be overcome to ensure the long-term efficacy and safety of CAR-T cell therapy for pediatric AML. In addition, the cost-effectiveness and scalability issues associated with delivering personalized CAR-T therapies demand further investigation. Overall, CAR-T cell therapy represents a promising therapeutic strategy for pediatric AML, holding immense potential in revolutionizing the treatment landscape of this aggressive disease. Future research should focus on refining CAR-T cell manufacturing techniques, optimizing antigen selection, and implementing combination therapies to further enhance the clinical outcomes of this innovative treatment modality.
Methods: Title: Treatment of Acute Myeloid Leukemia in Children by CAR-T Cell Therapy: A Promising Approach
Zahra Fathi , Ehsan Rezaei *
1 Biotechnology, Department of Biology, Faculty of Basic Science, University of Ale Taha, Tehran, Iran
2 Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran 1435916471, Iran
Abstract: Acute Myeloid Leukemia (AML) is a complex hematological malignancy primarily affecting children. The current standard of care for AML includes chemotherapy, stem cell transplantation, and targeted therapy. However, the clinical outcomes often remain suboptimal, highlighting the urgent need for novel therapeutic approaches. Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative treatment modality in various malignancies. The success of CAR-T therapy in pediatric leukemia, particularly in B-cell precursor Acute Lymphoblastic Leukemia (ALL), has encouraged exploration of its potential in AML. This article aims to review the current state-of-the-art clinical research and advancements in utilizing CAR-T cell therapy for treating pediatric AML. By targeting specific cell surface antigens expressed on leukemic blasts, CAR-T cells harness the immune system to recognize and eliminate cancer cells. High response rates, sustained remissions, and improved overall survival rates have been observed in preclinical and early-phase clinical trials utilizing CAR-T cell therapy in pediatric AML patients. However, several challenges, including antigen selection, antigen escape, cytokine release syndrome, and neurotoxicity, must be overcome to ensure the long-term efficacy and safety of CAR-T cell therapy for pediatric AML. In addition, the cost-effectiveness and scalability issues associated with delivering personalized CAR-T therapies demand further investigation. Overall, CAR-T cell therapy represents a promising therapeutic strategy for pediatric AML, holding immense potential in revolutionizing the treatment landscape of this aggressive disease. Future research should focus on refining CAR-T cell manufacturing techniques, optimizing antigen selection, and implementing combination therapies to further enhance the clinical outcomes of this innovative treatment modality.
Results: Title: Treatment of Acute Myeloid Leukemia in Children by CAR-T Cell Therapy: A Promising Approach
Zahra Fathi , Ehsan Rezaei *
1 Biotechnology, Department of Biology, Faculty of Basic Science, University of Ale Taha, Tehran, Iran
2 Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran 1435916471, Iran
Abstract: Acute Myeloid Leukemia (AML) is a complex hematological malignancy primarily affecting children. The current standard of care for AML includes chemotherapy, stem cell transplantation, and targeted therapy. However, the clinical outcomes often remain suboptimal, highlighting the urgent need for novel therapeutic approaches. Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative treatment modality in various malignancies. The success of CAR-T therapy in pediatric leukemia, particularly in B-cell precursor Acute Lymphoblastic Leukemia (ALL), has encouraged exploration of its potential in AML. This article aims to review the current state-of-the-art clinical research and advancements in utilizing CAR-T cell therapy for treating pediatric AML. By targeting specific cell surface antigens expressed on leukemic blasts, CAR-T cells harness the immune system to recognize and eliminate cancer cells. High response rates, sustained remissions, and improved overall survival rates have been observed in preclinical and early-phase clinical trials utilizing CAR-T cell therapy in pediatric AML patients. However, several challenges, including antigen selection, antigen escape, cytokine release syndrome, and neurotoxicity, must be overcome to ensure the long-term efficacy and safety of CAR-T cell therapy for pediatric AML. In addition, the cost-effectiveness and scalability issues associated with delivering personalized CAR-T therapies demand further investigation. Overall, CAR-T cell therapy represents a promising therapeutic strategy for pediatric AML, holding immense potential in revolutionizing the treatment landscape of this aggressive disease. Future research should focus on refining CAR-T cell manufacturing techniques, optimizing antigen selection, and implementing combination therapies to further enhance the clinical outcomes of this innovative treatment modality.
Conclusion: Title: Treatment of Acute Myeloid Leukemia in Children by CAR-T Cell Therapy: A Promising Approach
Zahra Fathi , Ehsan Rezaei *
1 Biotechnology, Department of Biology, Faculty of Basic Science, University of Ale Taha, Tehran, Iran
2 Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran 1435916471, Iran
Abstract: Acute Myeloid Leukemia (AML) is a complex hematological malignancy primarily affecting children. The current standard of care for AML includes chemotherapy, stem cell transplantation, and targeted therapy. However, the clinical outcomes often remain suboptimal, highlighting the urgent need for novel therapeutic approaches. Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative treatment modality in various malignancies. The success of CAR-T therapy in pediatric leukemia, particularly in B-cell precursor Acute Lymphoblastic Leukemia (ALL), has encouraged exploration of its potential in AML. This article aims to review the current state-of-the-art clinical research and advancements in utilizing CAR-T cell therapy for treating pediatric AML. By targeting specific cell surface antigens expressed on leukemic blasts, CAR-T cells harness the immune system to recognize and eliminate cancer cells. High response rates, sustained remissions, and improved overall survival rates have been observed in preclinical and early-phase clinical trials utilizing CAR-T cell therapy in pediatric AML patients. However, several challenges, including antigen selection, antigen escape, cytokine release syndrome, and neurotoxicity, must be overcome to ensure the long-term efficacy and safety of CAR-T cell therapy for pediatric AML. In addition, the cost-effectiveness and scalability issues associated with delivering personalized CAR-T therapies demand further investigation. Overall, CAR-T cell therapy represents a promising therapeutic strategy for pediatric AML, holding immense potential in revolutionizing the treatment landscape of this aggressive disease. Future research should focus on refining CAR-T cell manufacturing techniques, optimizing antigen selection, and implementing combination therapies to further enhance the clinical outcomes of this innovative treatment modality.
Keywords: Cancer, Leukemia, Immunotherapy, children